ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Category: dates
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
261_en
Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Transgene Reports First Quarter 2014 Financial Results
254_en
Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al. 8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64 Download the poster here Poster Presentation
Transgene Reports Fiscal Year 2013 Results and Provides Business Update
253_en
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al. Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article Publication
Immunotherapy for non – small – cell lung cancer: current approaches.
Elisabeth Quoix, et al. Current Respiratory Care Reports, 2014; 3 (1): 19-25 – Download the article Publication
Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Micaël De Meyer, et al. Journal for Immunotherapy of Cancer, 2013 – Download the article Publication